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Abstract. 
 
Fibroblast growth factors (FGF) play a criti-
cal role in bone growth and development affecting both 
chondrogenesis and osteogenesis. During the process of 
intramembranous ossiﬁcation, which leads to the for-
mation of the ﬂat bones of the skull, unregulated FGF 
signaling can produce premature suture closure or 
craniosynostosis and other craniofacial deformities. In-
deed, many human craniosynostosis disorders have 
been linked to activating mutations in FGF receptors 
(FGFR) 1 and 2, but the precise effects of FGF on the 
proliferation, maturation and differentiation of the tar-
get osteoblastic cells are still unclear. In this report, we 
studied the effects of FGF treatment on primary mu-
rine calvarial osteoblast, and on OB1, a newly estab-
lished osteoblastic cell line. We show that FGF signaling 
has a dual effect on osteoblast proliferation and differ-
entiation. FGFs activate the endogenous FGFRs lead-
ing to the formation of a Grb2/FRS2/Shp2 complex and 
activation of MAP kinase. However, immature osteo-
blasts respond to FGF treatment with increased prolif-
eration, whereas in differentiating cells FGF does not 
induce DNA synthesis but causes apoptosis. When ei-
ther primary or OB1 osteoblasts are induced to differ-
entiate, FGF signaling inhibits expression of alkaline 
phosphatase, and blocks mineralization. To study the 
effect of craniosynostosis-linked mutations in osteo-
blasts, we introduced FGFR2 carrying either the C342Y 
(Crouzon syndrome) or the S252W (Apert syndrome) 
mutation in OB1 cells. Both mutations inhibited differ-
entiation, while dramatically inducing apoptosis. Fur-
thermore, we could also show that overexpression of 
FGF2 in transgenic mice leads to increased apoptosis in 
their calvaria. These data provide the ﬁrst biochemical 
analysis of FGF signaling in osteoblasts, and show that 
FGF can act as a cell death inducer with distinct effects 
in proliferating and differentiating osteoblasts.
Key words: craniosynostosis • apoptosis • ﬁbroblast 
growth factors • ﬁbroblast growth factor receptors • os-
teoblast
 
Introduction
 
Mutations in fibroblast growth factor receptors (FGFR)
 
1
 
have been linked to a number of human autosomal domi-
nant skeletal disorders, including dwarfism and cranio-
synostosis syndromes, thus defining an important role for
FGF signaling in skeletogenesis (reviewed in Muenke and
Schell, 1995; Burke et al., 1998; Naski and Ornitz, 1998).
Missense mutations in FGFR1 and 2 have been found in a
variety of human craniosynostosis syndromes, which are
characterized by premature fusion of the calvarial sutures
and can lead to a variety of abnormalities including mal-
formed skull shape, proptosis and mental retardation.
However, studies on null mice have not been able to de-
fine a specific role for these receptors in osteogenesis due
to early embryonic lethality (Yamaguchi et al., 1994; Deng
et al., 1994; Arman et al., 1998).
Craniosynostosis is a result of improper bone formation
in the developing skull, which occurs by a complex and
poorly understood process termed intramembranous ossi-
fication. Mesenchymal cells enter the osteoblastic lineage
and undergo a spatial and temporal progression; early
preosteoblasts proliferate and then mature to osteoblasts
that can differentiate and produce a collagenous matrix, a
stage which is correlated with a decrease in proliferative
capacity (Stein et al., 1996). Subsequent mineralization of
the matrix results in the formation of the calvarial flat
bones. Ossification occurs outwards from bone centers
with the advancing bone margins separated by the sutures
that are comprised of mostly immature osteogenic stem
cells. The entire process is coordinated by the interplay of
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several signaling molecules such as the FGFs, BMPs,
hedgehog, and TGF
 
b
 
 (Wilkie, 1997; Kim et al., 1998). Al-
though clearly excessive or unregulated FGF signaling dis-
rupts normal intramembranous ossification, the effects of
FGFs on osteoblasts at different stages of maturation have
not been studied in detail.
Signaling from the FGF receptors can lead to prolifera-
tion, growth inhibition, or differentiation in different cell
types (Goldfarb, 1996), but it is not clear how these different
biological outcomes are achieved. Whereas in fibroblasts
and myoblasts, FGF treatment leads to the activation of
the RAS/MAP kinase pathway and to cell proliferation
(Kouhara et al., 1997; Saxton et al., 1997), in chondrocytes,
FGF signaling also leads to the activation of the STAT-1
pathway that is required for growth arrest (Sahni et al.,
1999). Several lines of evidence indicate that FGFs regu-
late both proliferation and differentiation in osteoblasts,
but apparently conflicting reports on the exact nature of
these effects exist in the literature, probably as a result of
differential effects of FGF depending on the stage of os-
teoblast maturation (Debiais et al., 1998; Pitaru et al.,
1993). Furthermore, most studies on the effect of FGFR
mutations in osteoblasts, thus far, have been restricted to
analysis of osteoblasts derived from craniosynostosis pa-
tients, and have been limited by the varying age of the pa-
tients and controls, and by the unknown effects of the
FGFR mutations on the previous in vivo progression of
these cells through maturation and differentiation (Lomri
et al., 1998; Fragale et al., 1999).
In this report we address these issues by studying the ef-
fect of FGF on immature osteoblasts and cells progressing
to differentiation both in primary mouse calvarial cells and
in a newly established murine osteoblast cell line, OB1.
Furthermore, to study the effect of known craniosynosto-
sis-linked mutations on osteoblast proliferation and differ-
entiation, we generated point mutations in the FGFR2
cDNA and stably expressed them in OB1 osteoblasts. The
genetic mutations that have been identified in FGFR2
generally lie in the extracellular domain of the receptor
(Burke et al., 1998). The mutation S252W in the linker re-
gion between the IgII and IgIII domains accounts for 65%
of the cases of Apert syndrome (Slaney et al., 1996; Wilkie,
1997), and the substitution of cysteine 342 in IgIII is the
most common mutation in FGFR2 associated with Crou-
zon, Jackson-Weiss, and Pfeiffer syndromes (Wilkie, 1997).
Biochemical analyses show that many of these mutations
disrupt the intra Ig domain disulfide bond and the un-
paired cysteines cause receptor-dimerization which leads
to constitutive receptor-activation (Galvin et al., 1996;
Mangasarian et al., 1997; Robertson et al., 1998).
Our results show that FGF signaling has distinct effects
on immature and maturing osteoblasts. Whereas imma-
ture cells are induced to proliferate, more differentiated
cells are not. Furthermore, treatment of differentiating os-
teoblasts with FGF leads to an increased rate of pro-
grammed cell death. In all cases FGF treatment results in
inhibition of differentiation, characterized by decreased
expression of alkaline phosphatase and by the absence of
mineralized nodules. In comparing the growth and differ-
entiation properties of OB1 osteoblasts expressing either
the wild-type FGFR2 or mutant receptors, FGFR2/S252W
(Apert) or FGFR2/C342Y (Crouzon), we find that cells
bearing the mutant receptor have a higher basal rate of
DNA synthesis. When the mutant receptor-containing os-
teoblasts are induced to differentiate the expression of al-
kaline phosphatase is strongly repressed and mineralized
bone nodules fail to form. Furthermore, apoptosis is dra-
matically increased. We also show that transgenic mice
overexpressing FGF2 have a greater proportion of cells
undergoing apoptosis in the developing calvarial osteo-
genic fronts compared with wild-type littermates. Thus,
FGF has multiple effects on osteogenesis which include
the induction of programmed cell death in differentiating
osteoblasts.
 
Materials and Methods
 
Cell Culture and Preparation of Primary Osteoblasts
 
Calvaria from newborn mice were dissected free of surrounding muscles
and soft tissues and washed in PBS containing penicillin and streptomycin.
Isolated calvaria were sequentially digested in 
 
a
 
MEM (GIBCO BRL),
containing 0.1% collagenase and 0.2% dispase at 37
 
8
 
C. Digested fractions
were collected every 10 min and fractions 2–5 were pooled. Cells were col-
lected by centrifugation and resuspended in 
 
a
 
MEM supplemented with
10% FCS. ROS 17/2.8 cells, a rat osteosarcoma cell line, was obtained
from Dr. D. Mellon (University of Wisconsin, Madison) and were grown
in DME containing 10% FCS. To study the differentiation of osteoblasts,
cells were cultured for up to 21 d in growth media containing ascorbic acid
(AA; 100 
 
m
 
g/ml) and 
 
b
 
-glycerophosphate (BGP; 4 mM) and medium was
changed every 3 d.
 
Immortalization of Osteoblasts
 
Primary osteoblasts were infected with a retrovirus (pBabe-puro) express-
ing the Polyoma large T-Antigen (Su et al., 1999). The cells were infected
for 1 h in the presence of 8 
 
m
 
g/ml of polybrene. The virus stock was pro-
duced in 293 cells as described previously (Bellosta et al., 1997). Clones
were selected using 4 
 
m
 
g/ml of puromycin for 2 wk. Immortalized clones
OB1-4 were characterized according to morphology, histochemical stain-
ing for alkaline phosphatase and for their ability to express osteocalcin
upon differentiation. Expression of Polyoma large T-Ag was determined
by immunofluorescence using an anti-Polyoma large T-Ag rat serum.
 
DNA Synthesis Assays and Alkaline
Phosphatase Staining
 
1 
 
3
 
 10
 
4
 
 cells were seeded on coverslips in 24-well plates in 
 
a
 
MEM me-
dium containing 10% FCS. After 24 h the cells were either serum starved
for 48 h in the presence of 0.4% FCS, or were induced to differentiate with
AA and BGP, in the presence or absence of FGF1 (10 ng/ml) and heparin
(10 
 
m
 
g/ml). Cells were labeled with 4 
 
m
 
g/ml of bromodeoxyuridine (BrdU;
Sigma-Aldrich) for 6 h at 37
 
8
 
C, and histochemical alkaline phosphatase
staining was performed according to manufacturer’s instructions (85L-2;
Sigma-Aldrich). Stained cells were then treated for 5 min with 0.5% Tri-
ton in PBS and for 15 min with 1.5 M HCl. After washing, analysis of
BrdU incorporation was performed using an anti-BrdU monoclonal anti-
body (Amersham) followed by anti–mouse secondary antibody conju-
gated with Texas Red (Molecular Probes 1:200). Nuclei were stained with
a solution of 1 
 
m
 
g/ml of Hoechst 33342 dye in PBS for 5 min. The fluores-
cence was visualized using a Zeiss Axiophot II microscope. The frequency
of S phase cells was calculated as a ratio of BrdU positive nuclei to the to-
tal Hoechst stained nuclei.
 
DNA Fragmentation and Apoptosis Assay
 
Cytosolic DNA from OB1 clones was isolated for fragmentation analysis
as previously described (Bellosta et al., 1997). DNA was isolated from
cells after 10 d of differentiation. Apoptotic nuclei of differentiating pri-
mary osteoblasts were visualized using Hoechst staining. Paraffin embed-
ded sections of 10-d-old post-frontal mouse sutures were processed for the
TUNEL assay (In situ cell death detection kit; Boehringer). Fluorescence
was visualized using a Zeiss Axiophot II microscope and TUNEL staining
was visualized by DAB. 
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Immunoprecipitation and Western Blot Analysis
 
Cells were lysed in RIPA buffer (10 mM, Tris-HCl, pH 7.2, 150 mM NaCl,
5 mM EDTA, 0.1% SDS, 1% Na deoxycholate, 1% Triton X-100) con-
taining protease and phosphatase inhibitors. 500 
 
m
 
g protein extracts was
immunoprecipitated with specific antibodies overnight at 4
 
8
 
C, after which
time, 50 
 
m
 
l of protein A–Sepharose (CL-4B, Amersham Pharmacia Bio-
tech) was added and incubated for 1 h at 4
 
8
 
C. The protein A antibody–
antigen complexes were washed extensively with the RIPA buffer and
separated on SDS-PAGE. Proteins were electrotransferred to nitrocellu-
lose membrane and incubated with the specific antibodies. Proteins were
visualized by ECL (Amersham Pharmacia Biotech). Antibodies against
FGFR1, 2, and 3 were purchased from Santa Cruz. Other antibodies used
included anti-FRS2 (provided by Dr. I. Lax, NYU Medical Center), anti-
SHP2 (Transduction Laboratories), anti-phosphotyrosine 4G10 (Onco-
gene Science), anti-phospho MAP kinase (NEB), anti-Erk2, and anti-Myc
antibodies (Santa Cruz).
 
Cloning and Expression of FGFR2 Mutants into
OB1 Clone
 
The stop codon was removed from a murine FGFR2 cDNA (Mansukhani
et al., 1992) by site-directed mutagenesis, replaced with a KpnI site and
cloned in frame with the myc epitope in pcDNA3.1/Myc-His vector (Invi-
trogen). A 3-kb PmeI fragment encoding the myc-tagged receptor was sub-
cloned in the HpaI site of the pLXSN retroviral vector under the mouse
Moloney leukemia virus LTR. Myc-tagged FGFR2/C342Y (Crouzon) and
FGFR2/S252W (Apert) mutations were also constructed as the FGFR2
above. The Crouzon mutation-containing cDNA (Mangasarian et al.,
1997) was myc tagged and subcloned into pLXSN as described above. The
Apert mutation, S252W, was generated by using site-directed mutagenesis
and was confirmed by DNA sequencing. The pLXSN vector carries the
neomycin resistance gene under the SV-40 promoter, allowing selection in
G418. pLXSN/FGFR2 constructs were cotransfected with an ecotropic
packaging vector in 293 cells in order to produce a replication-defective
retrovirus (Muller et al., 1991). OB1 cells were then infected with the virus
and pools of clones were selected using 400 
 
m
 
g/ml of G418 (GIBCO). The
expression of the receptors in OB1 clones were analyzed by Western blot
using an anti-Myc polyclonal antibody (Santa Cruz).
 
Von Kossa Staining
 
To detect mineralized nodules formed in vitro, cultures were fixed in 4%
paraformaldehyde for 10 min and rinsed with water. Cells were stained
with 1% silver nitrate, placed under a UV lamp for 30 min and rinsed with
water before treatment with 5% sodium thiosulfate for 2 min. Cells were
then washed twice with water and counterstained with 1% Safranin-O to
visualize the matrix.
 
Results
 
FGF Stimulates the Proliferation of Primary 
Osteoblasts and Newly Established Cell Lines
 
Earlier studies indicated that FGFs have a modest prolif-
erative effect on primary rat and human osteoblasts (Hur-
ley and Flokiewicz, 1996; Stein et al., 1996). To study the
biological effect of FGF on primary murine calvarial os-
teoblasts, we determined the percentage of cells undergo-
ing DNA synthesis by BrdU incorporation in the presence
and absence of FGF1, a ligand which binds all the FGFR
isoforms (Ornitz et al., 1996). Primary osteoblasts were
obtained by serial digestion of dissected calvaria from
1-d-old newborn mice and only first or second passage
cells were used for the assays. In primary murine osteo-
blasts, FGF1 modestly increases the fraction of BrdU-pos-
itive cells from 8% (untreated cells) to 21.5% (Fig. 1). This
weak proliferative effect is in contrast to that observed us-
ing primary embryonic fibroblasts, where FGF1 routinely
induces a 
 
.
 
10-fold increase in DNA synthesis (Bellosta et
al., 1997).
Primary osteoblast cultures contain a mixture of spin-
dle-shaped (immature) and cuboidal cells (mature) that
are at various stages of maturation. Upon initial plating
 
z
 
1–10% of primary osteoblasts are positive for alkaline
phosphatase (ALP). Whereas spindle-shaped cells are
negative for ALP staining, cuboidal cells range from nega-
tive to strongly ALP positive. When cells were simulta-
neously stained for BrdU and ALP, we observed that
strongly ALP-positive cells had not incorporated BrdU,
indicating that these mature cells have a low proliferative
capacity (data not shown). To determine the effect of
FGF1 on osteoblasts at different stages of maturation, we
performed BrdU incorporation assays on clonal cell lines
of the osteoblastic lineage that we derived by immortaliz-
ing primary osteoblasts with polyoma large T antigen (see
Materials and Methods). Four of these clones, OB1–OB4,
were characterized for their ability to differentiate and ex-
press the markers ALP and osteocalcin (OC). As summa-
rized in Table I, clones OB1 and 2 have a spindle-shaped
morphology and are negative for ALP and OC but steadily
increase ALP and OC expression upon differentiation. They
acquire a cuboidal morphology and form mineralized nod-
ules after 3 wk in differentiation medium. Clone OB3 and
4 have a more cuboidal morphology and express ALP and
OC but ALP expression is not appreciably increased upon
differentiation. Upon treatment with FGF1, clones OB1
and OB2 displayed a strong proliferative response, while
OB3 and OB4 have lower levels of stimulation, more simi-
lar to that of primary cultures. As seen in Fig. 1, clone
OB1 cells show an eightfold increase in BrdU incorpora-
tion after FGF treatment.
Clones OB1 and OB2 have the characteristics of imma-
ture osteoblasts, whereas clones OB3 and 4 represent
more mature stages in the differentiation pathway. Thus,
the weak proliferation seen in primary cultures is likely to
be an average of the responses of osteoblasts at different
stages of maturation. Clone OB1, which appears to be the
least differentiated and which has the highest proliferative
response to FGF was used for all further experiments.
 
FGF Signal Transduction in Osteoblasts
 
The strong proliferative response of fibroblasts to FGF is
Figure 1. Effect of FGF1 on BrdU incorporation: primary osteo-
blasts and OB1 cells. The cells were starved for 48 h in 0.4% FCS
then either untreated (2) or treated with FGF1 (10 ng/ml) and
heparin (10 ng/ ml) for 24 h, and BrdU (4 mg/ ml) was added from
18–24 h. 10% FCS was included as a positive control. The data
show the percentage of cells incorporating BrdU. Data shown are
mean 6 SD from a representative experiment. 
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mediated through FGF receptors 1 and 2 (Li et al., 1994),
whereas chondrocytes that are growth inhibited in their
response to FGF treatment express primarily FGFR3
(Sahni et al., 1999). To determine which FGF receptors
are expressed in primary calvarial osteoblasts and clone
OB1, we performed Northern analysis, using probes spe-
cific for the extracellular domains of the different FGF re-
ceptors. Primary murine osteoblasts, OB1, and ROS cells
were found to express the mRNAs for FGFR1, 2, and 3
(data not shown
 
)
 
.
We then tested whether the FGFR mRNAs detected
were expressed as functional FGF receptors that could be
activated by FGF1. Protein lysates were collected from
cells that had been untreated or treated with FGF1 for 10
min. Immunoprecipitation with FGFR-specific antibodies
followed by Western blotting with an anti-phosphoty-
rosine antibody showed that in ROS cells all three recep-
tor species are phosphorylated by FGF treatment. In pri-
mary osteoblasts and OB1 cells, however, only FGFR1
and FGFR2 are visibly phosphorylated (Fig 2 A). Similar
receptor activation experiments performed on clone OB2
cells also detect phosphorylation of only FGFR1 and
FGFR2 upon FGF treatment (data not shown).
When activated by ligand, receptor tyrosine kinases are
rapidly autophosphorylated on several tyrosine residues,
which are either essential for the catalytic kinase activity
of the receptor or serve as docking sites for target proteins.
The proliferative response to FGF in fibroblasts, for exam-
ple, requires activation of the MAP kinase pathway and
the phosphatase Shp2 (Saxton et al., 1997). Using protein
lysates from unstimulated and FGF-stimulated primary
osteoblasts and ROS cells, we studied the expression and
activation of many previously identified FGF signaling tar-
gets. The docking protein FRS2 links the FGF receptors to
the MAP kinase pathway by forming a complex with Shp2
and the adaptor protein Grb2 (Kouhara et al., 1997). Sam-
ples were immunoprecipitated with anti-FRS2 antibodies
and blotted with anti-phosphotyrosine, anti-Shp2, and anti-
Grb2 antibodies. Fig. 2 B shows that in both cell types,
FRS2 is tyrosine phosphorylated in response to FGF (90-
kD band). Shp2 (70 kD) and the adaptor protein Grb2 (20
kD) coimmunoprecipitate with FRS2 in FGF1-stimulated
cells. Activation of Shp2 is detected by a slight shift in mi-
gration due to hyperphosphorylation and broadening of
the 70-kD band in whole cell extracts which corresponds
to the 70-kD tyrosine phosphorylated band seen in FGF-
treated whole cell extracts (Fig. 2 C). Antibodies specific
for the phosphorylated form of MAP kinase detect the ac-
tivated form in FGF-stimulated primary, OB1 and ROS
cells.
Recent findings on FGF signaling in chondrocytes
(Sahni et al., 1999) show that activation of the STAT1 path-
way is required for growth arrest. To determine whether
the modest proliferation induced by FGF in primary os-
teoblasts may have been the result of the simultaneous ac-
tivation of the STAT1 growth inhibitory pathway, we veri-
fied whether STAT1 is activated in response to FGF.
However, FGF stimulation did not cause any detectable
activation of STAT1 in ROS, OB1 or primary calvarial
cells (data not shown). In conclusion, although osteoblasts
coexpress FGFR1, 2 and 3, the signaling pathways acti-
vated by FGF treatment in these cells appear to be similar
to those activated in fibroblasts.
Figure 2. FGF Signaling in
osteoblasts. (A) Activation
of FGFRs in primary osteo-
blast, OB1 (prOB), and ROS
cells. Cells were serum
starved overnight in 0.4%
FCS and were untreated (2),
or FGF1-treated (1), at 100
ng/ml for 10 min and lysed.
Total cell extract was sub-
jected to immunoprecipita-
tion with the anti-FGFR an-
tibody indicated and blotted
with anti-phosphotyrosine an-
tibody 4G10. (B) Complex
of FRS2, Shp2 and Grb2 in
osteoblasts. Total cell extract
from untreated (2) or FGF1-
treated (1) primary osteo-
blasts and ROS cells was
subjected to immunoprecipi-
tation (IP) with anti-FRS2
antibodies. Immunoprecipi-
tates were Western blotted
(WB) with anti-phosphoty-
rosine (aP-Tyr), or with the
indicated antibodies. 90-kD
FRS2, 70-kD Shp2, and 20-
kD Grb-2 bands are marked.
(C) Phosphorylation of Shp2
and MAP kinase. 40 mg of to-
tal lysates was blotted with anti–P-Tyr, anti-Shp2, or anti-phos-
pho MAP kinase (P-MAPK) antibodies.
 
Table I. Characterization of Osteoblast Clones
 
Cells
Stimulation of BrdU
incorporation by FGF1 Initial Morphology
ALP* OC
 
‡
 
Day 0 Day 5–8 Day 0 Day 5–8
 
OB1 8-fold Spindle shaped
 
61 12 1
 
OB2 6-fold Spindle shaped
 
61 12 1
 
OB3 1.5-fold Cuboidal
 
11 11 11 11
 
OB4 2-fold Cuboidal
 
1 1 11 111
 
Primary OB 3-fold Mixed
 
1 111 1 111
 
*Alkaline phosphatase (ALP) expression was determined by Northern analysis and by histochemical staining upon initial plating (day 0) and after 5–8 d of differentiation.
 
‡
 
Osteocalcin (OC) levels were assessed by Northern analysis upon initial plating (day 0) and after 5–8 d of differentiation. 
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Effect of FGF1 on Differentiating Osteoblasts
 
Long-term treatment of osteoblasts with ascorbic acid and
 
b
 
-glycerophosphate induces cell differentiation, character-
ized by increased expression of ALP and OC, cuboidal cel-
lular morphology, and increased matrix production, fol-
lowed by the mineralization of the extracellular matrix. To
determine the effect of continuous FGF1 treatment on os-
teoblast differentiation, primary murine calvarial osteo-
blasts and OB1 cells were induced to differentiate in the
presence or absence of FGF1 and heparin. After 3 wk, the
cells were stained for ALP expression and by the Von Kossa
method to visualize mineralized nodules. As seen in Fig. 3
A, differentiated primary osteoblasts stained strongly posi-
tive for ALP and mineralized areas were clearly visible.
Continuous treatment with FGF1 markedly suppressed
ALP expression and the formation of mineralized nodules.
A similar pattern was also observed in clone OB1 cells
(Fig. 6). The inhibition of ALP expression by FGF is re-
Figure 3. Effect of FGF
on osteoblast differentiation.
(A) Inhibition of alkaline
phosphatase (ALP) and min-
eralization. Primary calvarial
osteoblasts were maintained
in differentiation medium for
three weeks. FGF1 (10 ng/
ml) and heparin were added
from the start of the experi-
ments and the differentiation
medium was replaced every
3 d. Duplicate plates were
fixed and stained for alkaline
phosphatase enzymatic activ-
ity using Fast blue RR
(Sigma) and for mineraliza-
tion by Von Kossa staining.
Positive cells stain purple for
ALP expression and black ar-
eas indicate areas of mineral-
ization. (B) Effect of FGF on
osteoblast differentiation.
10,000 cells/well of primary
osteoblasts were plated on
coverslips in 10% FCS and
differentiation medium was
added to the wells at time 0.
FGF1 was added at 10 ng/ml.
BrdU (4 mg/ml) was added
during the last 6 h of each time point. Cells were stained for alkaline phos-
phatase expression and for BrdU incorporation. Percentage of cells incor-
porating BrdU are shown. The percentage of cells that were positive for al-
kaline phosphatase were counted for each time point and are indicated on
top of the graph. Data represent the mean of duplicate experiments. Bar,
800 mm.
 
versible and the number of ALP-positive cells increased
upon removal of FGF (data not shown).
We then examined whether the effect of FGF on prolif-
eration is altered as cells progress towards differentiation.
We measured BrdU incorporation and expression of ALP
in primary cells induced to differentiate either in the pres-
ence or absence of FGF1 after addition of differentiation
medium. Fig. 3 B shows that as the cells differentiate, the
rate of BrdU incorporation decreases steadily while ALP
expression increases. Before addition of differentiation
medium, 34% of the cells were incorporating BrdU. At
day 1 after differentiation, only 22% of cells were positive
for BrdU and this rate was reduced to 9.7% by day 3 and
to 3.7 and 2.8% at day 5 and 9, respectively. During this
time the percentage of ALP-positive cells increased from
1.6 to 38% at day 9. BrdU incorporation was only seen in
cells that were either negative or weakly positive for ALP,
i.e., cells that were strongly positive for ALP did not incor-
porate BrdU.
The effect of FGF1 on the level of DNA synthesis in the
differentiating osteoblasts is quite different from the pro-
liferative effect seen in the immature osteoblasts. At day 1,
there was no significant change in the level of BrdU incor-
poration, but at all subsequent time points FGF1 further
inhibited the rate of BrdU incorporation (Fig. 3 B). Thus,
as the proliferative capacity of differentiating osteoblasts 
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is progressively lost, FGF treatment no longer stimulates
DNA synthesis and in fact inhibits it further at the later
time points. ALP expression is drastically reduced by FGF
treatment at all time points. A similar pattern was seen in
differentiating OB1 osteoblasts (data not shown).
To determine if the lack of a mitogenic effect of FGF on
differentiating osteoblasts was related to an attenuation of
the MAP kinase pathway and/or alteration of FGFR acti-
vation, we studied the pattern of FGF receptor activation
in OB1 and OB2 cells that had been differentiated for two
weeks. Activation of FGFR1 and FGFR2, but not FGFR3,
was evident by IP-Western analysis similar to what was
found in immature osteoblasts that are growth stimulated
by FGF. The pattern of activation of Shp2 and FRS2 was
also unchanged and MAP kinase was still strongly acti-
vated as in immature osteoblasts (data not shown).
 
Expression of Activated FGFR2 in the OB1 Osteoblast 
Cell Line
 
Apert and Crouzon syndromes are predominantly associ-
ated with mutations in FGFR2. We created the most com-
mon Apert mutation in FGFR2, a serine 252 to tryptophan
substitution in the linker region between Ig loops II and
III in FGFR2 (Wilkie, 1997). Crouzon syndrome muta-
tions often involve the cysteine residues in Ig loop III and
we altered the most commonly mutated cysteine 342 to
tyrosine (Wilke, 1997). A wild-type FGFR2 cDNA and
the mutated FGFR2 cDNAs (FGFR2/S252W or FGFR2/
C342Y) were COOH-terminally tagged with a myc tag
and cloned in the pLXSN retroviral vector. We had previ-
ously shown that the Crouzon receptor is constitutively ac-
tivated, ligand unresponsive, and capable of transforming
NIH3T3 cells (Mangasarian et al., 1997). The Apert recep-
tor was reported to have higher affinity for FGF in solu-
tion assays (Anderson et al., 1998). We find that the Apert
mutation-bearing receptor can also transform NIH3T3
cells although with a slightly lower efficiency (
 
z
 
20%) than
the Crouzon mutation-bearing FGFR2 (data not shown).
Thus, the Apert mutation also causes a degree of ligand-
independent receptor activation.
To study the effects of the mutant receptors on osteo-
blast proliferation and differentiation, we introduced the
receptors into clone OB1 osteoblasts. Retroviral vectors
expressing myc-tagged wild-type or mutant FGFR2 cDNA
were used for infection and G418 resistant clones were se-
lected and checked for the expression of the integrated
constructs by Western blot analysis using anti-myc anti-
bodies. Pooled clones were used for further analysis and
tested for their ability to respond to FGF1 by receptor
phosphorylation. Cell lysates were subjected to immuno-
precipitation using anti-myc antibodies followed by West-
ern blotting analysis with anti-phosphotyrosine antibodies.
As seen in Fig. 4, cells expressing the wild-type receptor
(FGFR2) show phosphorylation of the receptor upon
stimulation with FGF1. The Apert mutation-bearing cells,
FGFR2/S252W exhibit some ligand-independent receptor
phosphorylation which is strongly enhanced by FGF1
treatment. As we had observed in fibroblasts, the FGFR2/
C342Y (Crouzon) receptor in osteoblasts is also detected
in an unglycosylated lower molecular mass form and its
phosphorylation in the Crouzon cells is constitutive and is
not further enhanced by FGF1 (Fig. 4 A). Western blot-
ting with anti-myc antibodies shows that similar amounts
of the myc-tagged receptor were immunoprecipitated in
the FGF1-treated and untreated samples of each clone.
The two bands recognized by the antibody are the ungly-
cosylated (lower) and the glycosylated (upper) forms of
FGFR2 (Fig. 4 B).
It has been shown that constitutive expression of ac-
tivated tyrosine kinase receptors causes no detectable
change in MAP kinase phosphorylation, most likely due to
the rapid turnover of phosphorylated proteins (Su et al.,
1997). Upon FGF treatment, inducible phosphorylation of
MAP kinase is apparent in the Apert and Crouzon recep-
tor-expressing cells (Fig. 4 C), which may indicate that the
endogenous FGF receptors can still be activated by the ad-
dition of ligand.
Figure 4. Expression and activation of FGFR2 and FGFR2 mu-
tant receptors in clone OB1. Parental OB1 cells as well as cells
stably expressing the FGFR2 wild-type, Apert, or Crouzon mu-
tants were serum starved for 24 h and left untreated (2) or
treated (1) with 100 ng/ml FGF1 for 10 min. Expression and acti-
vation of the myc-tagged receptors was tested by immunoprecipi-
tation with anti-myc antibodies followed by Western blotting as
indicated. (A) Western blot with anti-phosphotyrosine antibod-
ies (P-Tyr); (B) Western blot of with anti-myc antibodies; (C)
Whole cell extracts blotted with anti-phospho–MAP kinase anti-
bodies.
Figure 5. BrdU incorporation of OB1 cells, or cells expressing
FGFR2, Apert, or Crouzon mutations. Cells were serum starved
for 24 h in 0.4% FCS, then treated for 24 h with FGF (10 ng/
ml) 1 heparin, and with 10% FCS as a positive control. BrdU
was added from 13–24 h. The data show the percentage of cells
incorporating BrdU. 
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Effect of Activated FGFRs on Osteoblast Proliferation 
and Differentiation
 
We examined the rate of proliferation of the Apert and
Crouzon receptor-bearing osteoblasts in the presence or
absence of FGF. Fig. 5 shows that compared with control
cells or cells expressing the wild-type FGFR2, FGFR2/
S252W (Apert) and FGFR2/C342Y (Crouzon) mutant ex-
pressing cells exhibit a twofold increase in the basal level
Figure 6. Alkaline phosphatase and Von Kossa staining in OB1 cells expressing mutated FGFR2. Confluent cells were maintained in
differentiation medium for three weeks (100 mg/ml ascorbic acid and 4 mM b-glycerophosphate). FGF1 (10 ng/ml) and heparin (10 mg/
ml) were added where indicated after the first week. Medium was replaced every 3 d. (A) Plates were fixed and stained for alkaline
phosphatase enzymatic activity using Fast blue RR (Sigma). Positive cells stain purple. (B) Plates were fixed and stained with silver ni-
trate for mineralization by the Von Kossa method. Bone nodules stain black and the matrix stains red when counterstained with Safra-
nin O. Bars, 800 mm. 
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of DNA synthesis. In Crouzon cells, this basal rate is
weakly increased by FGF1 treatment, while Apert recep-
tor–expressing cells are stimulated from 22 to 54% BrdU
positive cells. Although the Crouzon mutation causes con-
stitutive receptor activation, it prevents ligand binding in
other cell types (Mangasarian et al., 1997). The stimulation
of proliferation by FGF1 in OB1 cells expressing the
Crouzon mutation is therefore probably due to activation
of the endogenous wild-type FGFRs. The Apert mutation
also causes an increase in osteoblast proliferation in the
absence of exogenous FGF indicating a degree of ligand
independence. However, the stronger proliferative re-
sponse by these cells upon FGF treatment is likely to be
due to the increased affinity of the Apert receptor for the
ligand (Anderson et al., 1998).
We then tested whether expression of the Apert or
Crouzon mutant FGFR2 affected the differentiation ca-
pacity of the OB1 cells. Cells were induced to differentiate
upon confluence with the addition of ascorbic acid and
beta glycerophosphate. They were analyzed for ALP ex-
pression and mineralized nodule formation after three
weeks in differentiation medium in the absence or pres-
ence of FGF1. Fig. 6 A shows that control OB1 cells were
well differentiated in the absence of FGF1 and stained
strongly positive for ALP. Addition of FGF1 inhibited the
expression of ALP both in control OB1 or in OB1 cells ex-
pressing wild-type FGFR2. In contrast, ALP expression in
OB1-Apert or Crouzon cells was undetectable even in the
absence of FGF1. Bone nodule formation was visualized
by Von Kossa staining where nodules stain black. Von
Kossa staining (Fig. 6 B) of parallel cultures showed that
in clone OB1 osteoblasts, mineralization is repressed by
addition of FGF1. In the mutant FGFR2-expressing cells,
mineralized nodules are absent even in the absence of
ligand indicating that the mutant receptors are constitu-
tively signaling. Large areas of red staining are visible (ma-
trix) indicating that some maturation does occur in the
mutant cells. Thus, constitutive expression of activated re-
ceptors in osteoblasts blocks ALP expression and mineral-
ization.
 
Activation of FGF Signaling during Osteoblast 
Differentiation Leads to Apoptosis
 
FGF treatment of immature osteoblasts increases prolifer-
ation. In contrast, we observed that continuous FGF treat-
ment of differentiating osteoblasts caused a clear increase
in cell death that became more apparent as differentiation
progressed. Similarly, cultures of OB1 cells expressing the
Crouzon or Apert FGFR2 mutations showed a large in-
crease in cell death upon differentiating conditions. We
thus investigated whether FGF treatment of osteoblast
cultures induced to differentiate caused apoptosis.
Upon differentiation, apoptosis was clearly visible in
Hoechst-stained nuclei of FGF-treated primary osteo-
blasts, as well as in the OB1 clone with large numbers of
cells displaying the characteristic apoptotic nuclear bleb-
bing and chromatin condensation. When induced to differ-
entiate, OB1 cells expressing the Crouzon or Apert muta-
tion undergo apoptosis even in the absence of added FGF.
A quantitation of the percent of apoptotic nuclei during
differentiation of primary osteoblasts is shown in Fig. 7 A.
In untreated differentiating cultures, there is no apprecia-
ble increase in apoptosis over 14 d, while in cultures con-
tinuously treated with FGF1, the number of apoptotic
nuclei is increased to 38%. We analyzed DNA from un-
treated and FGF-treated samples of clone OB1, FGFR2/
S252W (Apert) and FGFR2/C342Y (Crouzon) cells that
had been differentiated for 10 d, and checked for the
DNA-laddering pattern typical of apoptotic cells. As seen
in Fig. 7 B, DNA laddering is clearly visible in FGF-
treated control OB1 cells indicating that activation of FGF
signaling during differentiation induces programmed cell
death. The same high degree of DNA laddering is ob-
served in the OB1 cells expressing the mutated receptors,
showing that constitutive FGFR2 activation is sufficient to
induce apoptosis even in the absence of ligand stimulation
(Fig. 7 B).
Apoptosis is not generally observed in response to FGF,
and in fact, FGF protects fibroblasts from apoptosis in-
duced by serum-starvation (Bellosta et al., 1997). We
therefore examined the signaling molecules activated by
FGF that may be implicated in the cell death response.
Since activation of AKT by PI-3 kinase is responsible
for the protective effect of growth factors on apoptosis
(Kennedy et al., 1997), we examined whether this pathway
Figure 7. Apoptosis in differentiating osteoblasts treated with
FGF. (A) Cells were plated on coverslips in 24-well plates and
cultured in differentiation medium for 14 d in the absence (2) or
presence (1) of FGF1 (10 ng/ml 1 heparin). Cells were fixed on
the indicated days. Hoechst dye–stained nuclei from at least
seven different microscope fields were counted and apoptotic nu-
clei calculated as a percentage of total cells. Data shown are
means 6 SD from a representative experiment. (B) Cells were
cultured for 10 d in differentiation medium. FGF1 was added at
10 ng/ml in the (1) lanes and the medium was changed every 3 d.
DNA was extracted, electrophoresed on 0.8% agarose gel and vi-
sualized with ethidium bromide. Control, OB1 cells with vector
alone. 
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was impaired in differentiating osteoblasts. FGF treatment
leads to the activation of AKT by serine phosphorylation
(Miho et al., 1999). Using antibodies specific for phosphor-
ylated AKT, we tested whether AKT was activated in
response to FGF in OB1 osteoblasts. Fig. 8 A shows
that while AKT phosphorylation is strongly increased in
NIH3T3 fibroblasts after 15 min of treatment with FGF1,
OB1 cells show no increase of AKT phosphorylation in
proliferating or differentiating cells. MAP kinase was
equally activated in NIH3T3 and OB1 cells. We then ex-
amined the steady state levels of phospho-AKT in OB1
cells induced to differentiate for 5 or 9 d. No increase was
seen in phospho-AKT during differentiation both in the
presence or absence of FGF1. We also found that the pro-
apoptotic factor Bax is induced during differentiation and
is further increased in the presence of FGF1. On the other
hand, the anti-apoptotic factor Bcl2 is also induced during
differentiation but is somewhat delayed in cells treated
with FGF (Fig. 8 B). Thus, lack of phospho-AKT induc-
tion together with the increase in Bax level and the delay
in Bcl2 accumulation may all contribute to the apoptotic
effect of FGF seen in differentiating osteoblasts.
To determine whether FGF induced apoptosis also oc-
curred in vivo, we examined a mouse model of unregu-
lated FGF signaling. These animals overexpress a trans-
genic FGF2 under the control of the PGK promoter, and
exhibit chondrodysplasia and abnormal skull formation
(Coffin et al., 1995). We therefore examined calvarial sec-
tions from these mice and compared them to wild-type lit-
termates. Serial sections of the post-frontal suture of 10-d-
old mice were stained by the TUNEL assay to visualize
apoptotic nuclei. Fig. 9 shows that compared with wild-
type littermates, calvarial section of transgenic animals
show a clear increase in apoptotic nuclei in the post frontal
suture region. The positively stained cells are concentrated
at the osteogenic front representing the position of differ-
entiating cells. The immature cells in the middle of the su-
ture are unstained. Although the relevance of this obser-
vation to the cranial malformations observed in these
animals will require further investigation, these data show
that unregulated FGF signaling can induce apoptosis in
differentiating osteoblasts in vivo.
 
Discussion
 
The process of osteogenesis occurs in the developing cal-
varial bones, in the long bones, and continues in the adult
to maintain the balance between bone formation and re-
sorption. Although some progress has been made in un-
derstanding osteogenesis and the biology of premature su-
ture closure, much, including the role of FGF, remains to
be clarified. Whereas there has been general agreement
that FGF stimulates the proliferation of osteoblasts in
vitro, FGF appears to inhibit expression of differentiation
markers ALP, OC in human and rat calvarial cells (Stein
et al., 1996; Hurley and Florkiewicz, 1996), but increases
the levels of ALP, OC, and differentiation of osteogenic
precursors in the bone marrow (Pitaru et al., 1993). Re-
ports on osteoblasts analyzed from patients with FGFR2-
linked craniosynostosis are also difficult to reconcile.
Lomri et al. (1998) report that osteoblasts established
from an Apert patient with an S252W mutation in FGFR2
have no alteration in their proliferation rate when com-
pared with age-matched control cells, but express higher
levels of differentiation markers. Fragale et al. (1999)
studied osteoblasts from a patient with Apert syndrome
with FGFR2/P253R and reported that the cells had de-
creased proliferation, higher ALP, and increased mineral-
ization compared with age-matched control cells. Addi-
tionally, osteoblasts from a Pfeiffer’s syndrome patient
with FGFR2/C342R, an activating mutation also found
in Crouzon’s syndrome, showed decreased proliferation,
higher ALP, but absence of mineralization. The effect of
these mutations on osteoblast proliferation and differenti-
ation cannot be easily compared because of varying ages
of the patients and heterogeneity in the maturation stage
of the initially isolated osteoblasts. Additionally, neither of
these reports ascertained the expression of FGFRs, thus
leaving the possibility that the mutant receptor may be
downregulated in some cases (see below).
In this report, we studied the effect of FGF on osteo-
blasts before and during differentiation. We isolated
clonal populations of osteoblasts at different stages of
maturation and compared their responses to FGF. The
clone OB1, an immature osteoblastic cell line that we gen-
erated, can undergo differentiation, upregulate expression
of ALP and OC, and form mineralized nodules, thus pro-
viding a good model for osteoblastic differentiation. We
found that FGF-induced stimulation of proliferation cor-
relates with an immature phenotype whereas differentiat-
ing cells that are producing matrix and steadily upregulat-
ing ALP lose their proliferative response to FGF and
respond with increased apoptosis. FGF treatment re-
presses ALP expression and further inhibits the rate of
DNA synthesis at later times during differentiation. We
show that FGF signaling activates FRS2, Shp2, and the
MAP kinase in osteoblasts and that there is no activation
of STAT1. Although we find no detectable differences in
activation of FGF receptors or MAP kinase in proliferat-
Figure 8. Expression activa-
tion of AKT, bax and bcl2 in
osteoblasts. (A) Effect of
FGF on AKT activation in
osteoblasts. Total cell ex-
tracts were prepared from
cells that were serum starved
overnight in 0.4% FCS and
were either left untreated
(2) or treated with FGF1
(1) at 100 ng/ml for 15 min.
OB1 diff, cells were differen-
tiated for 7 d. Antibodies
used are indicated. Anti-
phospho AKT (anti–P-AKT)
or anti-phospho MAPK
(P-MAPK). (B) Effect of
FGF on expression of AKT,
bax, and bcl2 in differentiat-
ing osteoblasts. Whole cell
extracts of cells that had been
maintained in differentiation medium with 10% FCS for the indi-
cated days in the absence (2FGF1) or presence (1FGF1) at 10
ng/ml. Antibodies used are indicated. 
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ing osteoblasts compared with osteoblasts that have been
differentiated for two weeks, there may be differences at
later times during differentiation or in other pathways.
We introduced two FGFR2 mutants in OB1 osteoblasts.
Both mutations, FGFR2/S252W (Apert) and FGFR2/C342Y
(Crouzon) increase the proliferative rate of OB1 cells and
block the appearance of ALP and mineralized nodules
upon differentiation. As in wild-type osteoblasts, the mu-
tant receptor-expressing cells lose their proliferative ca-
pacity upon differentiation and display a striking increase
in apoptosis. Thus, these constitutively activated receptors
mimic the effect of treatment with exogenous FGF. Since
the inhibition of proliferation during differentiation corre-
lates with an increase in the rate of apoptosis, it suggests
that increased programmed cell death may account for the
reduced rate of DNA synthesis and the block in mineral-
ization seen in these cultures. Furthermore, in vivo, we
see that mice overexpressing FGF2 have increased apop-
tosis in the calvarial suture compared with wild-type lit-
termates. These data indicate that our findings on FGF-
induced apoptosis have relevance in vivo. Although it is
unclear presently how this might affect the rate of osteo-
genesis and suture closure, we propose that FGF-induced
apoptosis may represent a homeostatic mechanism con-
trolling the rate of osteoblast differentiation and osteogen-
esis.
Apoptosis during osteogenesis has not been well studied
but there are clear indications that it must play an impor-
tant role in normal bone formation and remodeling. A ma-
jor fraction of osteoblasts at bone remodeling sites cannot
be accounted for and probably undergo apoptosis (Jilka et
al., 1998) and the anabolic effect of PTH is due to its anti-
apoptotic effect on osteoblasts (Jilka et al., 1999). A recent
report by Rice et al.
 
 
 
(1999) shows that apoptotic osteo-
blasts are present in the developing mouse calvarial bones.
The FGFs have not previously been implicated in causing
programmed cell death and generally protect from apop-
totic effects induced by serum starvation (Hill et al., 1997;
Bellosta et al., 1997). The fact that FGF induces apoptosis
in differentiating osteoblasts in the presence of serum sug-
gests a novel signaling mechanism by which FGF may reg-
ulate the rate of osteoblast proliferation and differentia-
tion.
The mechanism by which FGF signaling increases pro-
liferation in immature osteoblasts, and paradoxically in-
hibits DNA synthesis and increases apoptosis in differenti-
ating cells is not clear at the moment. Differentiating
osteoblasts could be expressing adaptors or substrates
which are different from those expressed in immature cells
and which could direct FGF signaling to novel pathways.
Our data show that FGF signaling does not activate the
anti-apoptotic AKT pathway in osteoblasts, which is in
contrast to other cell types (Miho et al., 1999). Although
we found no differences in AKT activation in immature
versus mature osteoblasts, the lack of this response may
contribute to the increased apoptosis in differentiating os-
Figure 9. Apoptosis in mouse calvarial sections. Sections of 10-d-old post-frontal suture of FGF2 transgenic (Tg) and wild-type (wt) lit-
termates. Tissues were starved with Toluidine blue (upper panel) and for apoptosis using the TUNEL assay (lower panel). Cells in apop-
tosis are stained brown. Upper panel stained with Toluidine blue. OF, osteogenic front. The arrows point to the endocranial surface of
the sections. Bar, 200 mm. 
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teoblasts perhaps due to conflicting signals of proliferation
and growth arrest similar to what has been observed for
c-myc–induced apoptosis (Evan et al., 1992). However, in
our experiments we find no increase in c-myc levels during
differentiation (data not shown). Osteoblasts provide a
good system in which to investigate the signaling pathways
leading to divergent cellular response.
Our experiments suggest that the role of FGF signaling
in intramembranous ossification could be dual. Initially
FGF would stimulate the proliferation of immature osteo-
blasts, thus increasing the pool of osteoblast progenitors,
and then act as a “brake” controlling the number of osteo-
blasts that undergo terminal differentiation. Alternatively,
the concentration of apoptotic cells at the osteogenic
front, seen in FGF2 transgenic mice, may imply that apop-
tosis enhances the progress of the bone fronts by clearing
cells which must die in order for mineralization to occur.
The increase of proliferation of immature cells by FGF
and then an increase in apoptosis at the front may eventu-
ally result in accelerated suture closure. This latter hypoth-
esis could be reconciled with the in vivo effects of FGF in
enhancing bone formation (Mundy et al., 1999) and the
craniosynostosis due to activated FGFRs. A detailed ex-
amination of apoptosis during calvarial osteogenesis and
the effect of FGF should provide more insight into this
process. The creation of mouse models of craniosynosto-
sis, which is in progress in several laboratories, including
ours, will help in answering these questions.
FGF2 and FGF9 are the ligands that are likely to be
involved in FGF signaling during calvarial osteogenesis
(Rice et al., 2000). The presence and concentration of
ligand at different stages of osteoblast maturation will de-
termine where and when FGF signaling is activated. Al-
though it is unlikely, other FGFs could have different ef-
fects on differentiating osteoblasts. The timing of FGF
signaling determined by regulation of receptor expression
is also likely to be an important consideration in under-
standing cranial suture closure. FGF4 beads applied to the
embryonic suture mesenchyme in the developing skull in-
creases proliferation of undifferentiated cells but actually
delays suture closure. However, FGF4 beads applied on
the osteogenic front at the same stage of embryonic devel-
opment accelerate suture closure (Kim et al., 1998). If
FGF signaling is somehow downregulated or limited as
cells move towards the front, it would allow differentiation
to proceed. FGFR2 is expressed primarily in the preosteo-
blasts of the osteogenic front (Iseki et al., 1997,
 
 
 
1999). If
FGFR2 mRNA is downregulated, then its proliferative ef-
fect will be self limiting and cells may be able to progress
to a later stage of differentiation. Furthermore, mutant
FGFR2 genes that lead to craniosynostosis should be tran-
scriptionally regulated in the same way as the normal
gene. Thus, the regulation of FGFR2 expression at differ-
ent stages of osteoblast maturation will be a critical factor
in understanding the biology of craniosynostosis.
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